A Case Report of Immune Thrombocytopenia after ChAdOx1 nCoV-19 VaccinationChAdOx1 nCoV-19 백신 접종 후 면역 혈소판 감소증의 증례 보고Case Reports Published on 2021-11-082022-09-12 Journal: Journal of Korean medical science [Category] MERS, SARS, 진단, [키워드] acute respiratory syndrome Adenovirus adverse event AstraZeneca Autoimmune ChAdOx1 ChAdOx1 nCoV-19 characterized clinical Coagulopathy coronavirus coronavirus disease COVID-19 described Dexamethasone diagnosed Evidence first dose gingival bleeding High-dose identify Immune thrombocytopenia Intravenous immunoglobulin laboratory result manifestation mechanism mRNA-1273 mRNA-based Pfizer-BioNTech Platelet receiving report SARS-CoV-2 thrombocytopenia treated Treatment vaccination Vaccine [DOI] 10.3346/jkms.2021.36.e306 PMC 바로가기 [Article Type] Case Reports
Adverse events of active and placebo groups in SARS-CoV-2 vaccine randomized trials: A systematic reviewResearch Paper Published on 2021-10-282022-10-30 Journal: The Lancet Regional Health - Europe [Category] COVID-19, [키워드] Ad26.COV2.S Adenovirus adopted Adverse adverse event adverse events AEs approved BNT162b2 clinical trial clinical trials database Effect Effects event fatigue favor finding first dose funding group groups headache identify in both group injection local pain mRNA mRNA vaccines mRNA-1273 mRNA-based myalgia nocebo effect Occurrence Pain Participants Placebo placebo group placebo recipient placebo recipients Randomized Randomized control trials Reactions recipients regulatory agencies Relative risk reported Safety assessment SARS-CoV-2 vaccine SARS-CoV-2 vaccines systematic review the placebo group the vaccine Vaccine with COVID-19 [DOI] 10.1016/j.lanepe.2021.100253 PMC 바로가기 [Article Type] Research Paper
Comparison of antibody and T cell responses elicited by BBIBP-CorV (Sinopharm) and BNT162b2 (Pfizer-BioNTech) vaccines against SARS-CoV-2 in healthy adult humans건강한 성인에서 SARS-CoV-2에 대한 BBIBP-CorV(Sinopharm) 및 BNT162b2(Pfizer-BioNTech) 백신에 의해 유도된 항체 및 T 세포 반응의 비교Original Article Published on 2021-10-112022-09-11 Journal: GeroScience [Category] MERS, SARS, 치료법, [키워드] adaptive Adaptive immunity Analysis anti-SARS-CoV-2 anti-SARS-CoV-2 antibodies Anti-spike antibody BBIBP-CorV BNT162b2 cell-mediated immune response Cell-mediated immune responses Convalescent patients cumulative domain effective elicit elicited epitope Epitopes evaluate healthy healthy individuals Human humoral IFNγ ELISpot assay IFNγ-producing T cells IFNγ IgA antibodies IgA antibody IgG immune response immune responses Immunity immunologically in healthy individuals inactivated injected investigated Live virus membrane mRNA mRNA vaccine mRNA-based much lower nucleocapsid participant pattern Pfizer-BioNTech Protein Proteins Quantitative RBD S protein epitopes SARS-CoV-2 SARS-CoV-2 virus Sinopharm supplementary material T cell T cell response target the S protein These data vaccination Vaccine virus Volunteer [DOI] 10.1007/s11357-021-00471-6 PMC 바로가기 [Article Type] Original Article
Nanotechnology Interventions in the Management of COVID-19: Prevention, Diagnosis and Virus-Like Particle VaccinesReview Published on 2021-10-042022-10-28 Journal: Vaccines [Category] COVID-19, [키워드] addressed adverse effects antiviral medication approved claimed coated COVID-19 COVID-19 transmission Critical database Diagnosis Direct Diseases elicit equipment Google Scholar immune response imperative information lack Lipid nanoparticle Masks Moderna mRNA-based nanoparticle Nanotechnology Novavax pandemic Particle Pfizer Phase 3 trials prevention Probability Protective reported SARS-CoV-2 Science Transport Treatment Vaccine Vaccines variable Virus-like particle virus-like particle vaccine virus-like particle vaccines [DOI] 10.3390/vaccines9101129 PMC 바로가기 [Article Type] Review
Function Is More Reliable Than Quantity to Follow Up the Humoral Response to the Receptor-Binding Domain of SARS-CoV-2-Spike Protein after Natural Infection or COVID-19 VaccinationArticle Published on 2021-09-302022-10-28 Journal: Viruses [Category] COVID-19, SARS, [키워드] absence anti-S antibody antibodies antibody assay Antibody titer average binding Cohort COVID-19 COVID-19 vaccine declined detectable dose examination function functional humoral humoral immune response IgG titer immune response impacted indicate induce Infection Like MONITOR mRNA mRNA-based naïve subjects natural natural immune response natural infection neutralization Neutralizing activity neutralizing antibody Neutralizing antibody response Novel coronavirus pandemic Patient protection Protein quantified quantity remained response robust SARS-CoV-2 sera seroconverting serology subject subjects subset the SARS-CoV-2 vaccination Vaccine vaccine dose variants of concern viral neutralization Virus neutralization [DOI] 10.3390/v13101972 PMC 바로가기 [Article Type] Article
Axonal-Variant Guillian-Barre Syndrome Temporally Associated With mRNA-Based Moderna SARS-CoV-2 VaccineNeurology Published on 2021-09-262022-10-31 Journal: Cureus [Category] COVID-19, [키워드] adverse event appear association cerebrospinal fluid clinical symptom COVID-19 CSF Diagnosis effective Epidemiological study Evidence gbs following covid-19 vaccine gbs variant IMPROVE Infection prevention Moderna mRNA-1273 vaccine mRNA-based mRNA-based SARS-CoV-2 vaccine mRNA-based vaccine outcomes physician SARS-CoV-2 SARS-CoV-2 vaccine second dose Treatment [DOI] 10.7759/cureus.18291 PMC 바로가기 [Article Type] Neurology
First description of immune complex vasculitis after COVID-19 vaccination with BNT162b2: a case reportBNT162B2를 사용한 COVID-19 백신 접종 후 면역 복합 혈관염에 대한 첫 번째 설명 : 사례 보고서Case Reports Published on 2021-09-162022-09-01 Journal: BMC Infectious Diseases [Category] SARS, 진단, [키워드] abdomen association bloody bloody diarrhoea BNT162b2 Case report cirrhosis clinical manifestation clinical manifestations COVID-19 COVID-19 infection COVID-19 infections COVID-19 vaccination diarrhoea elevated hands hypersensitivity hypersensitivity reaction immune complex Immune complex vasculitis inflammatory markers injection Laboratory laboratory findings Laboratory testing leg Liver cirrhosis lower abdomen male mRNA-based of BNT162b2 oral steroid Physical examination reported resolved Steroids the patient Treatment Type three hypersensitivity vaccination Vasculitis written report [DOI] 10.1186/s12879-021-06655-x PMC 바로가기 [Article Type] Case Reports
Development of an mRNA-LNP Vaccine against SARS-CoV-2: Evaluation of Immune Response in Mouse and Rhesus MacaqueArticle Published on 2021-09-102022-10-28 Journal: Vaccines [Category] COVID-19, [키워드] approaches C57BL/6 CAP Characteristics cytotoxicity demonstrated development Efficacy ELISA ELISA assay encapsulation evaluated feature IFN-γ IL-4 immune response immunized mice in vitro in vitro transcription infused injected injection introduced Lipid nanoparticle Liposome LNP macaque marker mice Moderna mouse mRNA mRNA vaccine mRNA-based mRNA-vaccine Neutralizing neutralizing antibody nucleoside analog Pfizer/BioNTech produced response rhesus SARS-CoV-2 secretion Spike protein stability the vaccine Vaccine virus VNT [DOI] 10.3390/vaccines9091007 PMC 바로가기 [Article Type] Article
Novel virus-like nanoparticle vaccine effectively protects animal model from SARS-CoV-2 infection새로운 바이러스 유사 나노 입자 백신은 SARS-CoV-2 감염으로부터 동물 모델을 효과적으로 보호합니다Research Article Published on 2021-09-072022-09-10 Journal: PLoS Pathogens [Category] 변종, 신약개발, 진단, [키워드] animal model blocked boost cell entry Clinical sign Clinical signs contribute coronavirus COVID-19 pandemic curtail develop domain effective Effectiveness Efficacy elicit FIVE help host receptor human population immune response immune responses Immunity immunized mice inhibited lack mice mRNA mRNA-based neutralized Neutralizing Neutralizing antibodies neutralizing antibody Neutralizing antibody response novel pathological change pathological changes PROTECT Protein Protein-based vaccines provide RBDs Receptor-binding domain recombinant reducing Safe SARS-CoV-1 SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 RBD SARS-CoV-2 strains SARS-CoV-2 vaccine SARS-CoV-2 vaccines SARS-CoV-2 variants Spread Strains study period subunit vaccines the cell the RBD Vaccine vaccine candidate variant variants variants of SARS-CoV-2 variety Viral viral vector-based VLP [DOI] 10.1371/journal.ppat.1009897 PMC 바로가기 [Article Type] Research Article
Immunological Response Against SARS-COV-2 After BNT162b2 Vaccine Administration Is Impaired in Allogeneic but Not in Autologous Stem Cell Transplant RecipientsOncology Published on 2021-09-062022-10-31 Journal: Frontiers in Oncology [Category] COVID-19, [키워드] administration Against Allogeneic allogeneic HSCT Antibody Response Antibody titer autologous autologous HSCT B cell B lymphocyte BNT162b2 CD19 CD19+ CD20 CD56+ Cell control group correlated correlation COVID-19 immunity cyclosporine Cytometry develop Efficacy evaluate Flow glycoprotein healthy subjects HSCT HSCT recipients immune response immunosuppressive Impaired mRNA-based natural killer negatively affected NK cell NK cells Patient performed Peripheral blood Pfizer-BioNTech platform Prospective Study recipient response rituximab SARS-CoV-2 IgG SARS-CoV-2 vaccine SARS-CoV2 second dose Seroconversion serum sample STEM Stem cell transplantation submitted T cells tested the antibody response the Spike Transplant vaccination Vaccine [DOI] 10.3389/fonc.2021.737300 PMC 바로가기 [Article Type] Oncology